Lenuxin (Escitalopram)

Escitalopram selectively blocks the serotonin transporter (SERT) on presynaptic neurons, preventing reuptake of serotonin into the nerve terminal. This raises the level of serotonin in the synaptic cleft, enhancing serotonergic neurotransmission, which is associated with improved mood and reduced anxiety.

The appropriate dose of Lenuxin is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for escitalopram in pregnancy and lactation are limited. Clinicians weigh potential benefits against risks before prescribing to pregnant or nursing women. Patients should discuss any concerns with their healthcare provider to make an informed decision.

To request Lenuxin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Lenuxin (escitalopram) is a highly selective SSRI, offering a favorable side‑effect profile compared with less selective agents. Compared with older SSRIs, it often requires lower doses for therapeutic effect and may have fewer drug‑interaction concerns, though individual response varies.

Lenuxin should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Lenuxin is taken orally, usually once daily with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks include the potential for serotonin syndrome, especially when combined with other serotonergic drugs, and the emergence of suicidal thoughts or behaviors, particularly in younger adults during early treatment. Any signs of severe allergic reaction or cardiac arrhythmia require immediate medical attention.

Lenuxin is contraindicated in patients who have taken monoamine oxidase inhibitors within the past 14 days, those with known hypersensitivity to escitalopram, and individuals using pimozide or thioridazine due to the risk of cardiac complications. Clinicians should assess each patient’s medical history before prescribing.